Shield Therapeutics PLC Withdrawal of all oppositions by TEVA (3927C)
19 October 2020 - 5:00PM
UK Regulatory
TIDMSTX
RNS Number : 3927C
Shield Therapeutics PLC
19 October 2020
Shield Therapeutics plc
("Shield" or the "Group" or the "Company")
Withdrawal of all oppositions by Teva Pharmaceutical Industries
Ltd
London, UK, 19 October 2020: Shield Therapeutics plc (LSE: STX),
a commercial stage, pharmaceutical company with a focus on
addressing iron deficiency with its lead product
Feraccru(R)/Accrufer(R) (ferric maltol), announces an update on its
opposition proceedings with Teva Pharmaceutical Industries Ltd
(TEVA).
Following the announcements to shareholders on 3 June 2019 and 1
May 2020 Shield has received notice that TEVA has withdrawn both
its appeal against the European Patent Office's decision with
regard to Shield's patent No.2668175, which covers a "Process for
preparing an iron hydroxypyrone" and their opposition with regard
to Shield's patent No.3160951 which covers "Crystalline Forms of
Ferric Maltol."
With respect to European Patent No.2668175 "Process for
preparing an iron hydroxypyrone" the withdrawal of the appeal means
that the decision by the Opposition Division of 3 April 2019 has
become final and that the patent will be maintained as amended on
14 March 2019.
Further to the withdrawal of the opposition to European Patent
No.3160951 "Crystalline Forms of Ferric Maltol" the European Patent
Office has today confirmed that it has no cause to continue the
proceedings of its own motion and that the hearing is duly
cancelled. This means that the patent is maintained as granted and
will continue to provide protection through to October 2035.
Commenting on this outcome Lucy Huntington-Bailey, Shield's
General Counsel said: "We are delighted that the European Patent
Office has decided not to continue proceedings following the
withdrawal of the opposition by TEVA and saw no reason to amend the
patent as originally granted. This publicly demonstrates the
validity of the patent and the strength of defence that Shield
provided to robustly defend its patents."
For further information please contact:
Shield Therapeutics plc www.shieldtherapeutics.com
Tim Watts, CEO +44 (0)20 7186 8500
Lucy Huntington-Bailey, General
Counsel +44 (0)19 1511 8500
Nominated Adviser and Joint
Broker
Peel Hunt LLP
James Steel/Dr Christopher
Golden +44 (0)20 7418 8900
Joint Broker
finnCap Ltd
Geoff Nash/Matt Radley/Alice
Lane +44 (0)20 7220 0500
Financial PR & IR Advisor
Walbrook PR +44 (0)20 7933 8780 or shield@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7584 391
Paul McManus/Lianne Cawthorne 303
About Shield Therapeutics plc
Shield is a de-risked, specialty pharmaceutical company focused
on commercialising its lead product, Feraccru(R)/Accrufer(R), a
novel, stable, non-salt based oral therapy for adults with iron
deficiency with or without anaemia. Feraccru(R)/Accrufer(R) has
been approved for use in the United States, European Union, UK and
Switzerland and has exclusive IP rights until the mid-2030s.
Feraccru(R) is commercialised in the UK and Europe by Norgine B.V.
and the Company is currently in the process of selecting a
commercialisation partner for the US market. Shield also has an
exclusive licence agreement with Beijing Aosaikang Pharmaceutical
Co., Ltd., for the development and commercialisation of
Feraccru(R)/Accrufer(R) in China, Hong Kong, Macau and Taiwan.
For more information, please visit www.shieldtherapeutics.com .
Follow Shield on Twitter @ShieldTx
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCGZMMGNVDGGZM
(END) Dow Jones Newswires
October 19, 2020 02:00 ET (06:00 GMT)
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Apr 2024 to May 2024
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From May 2023 to May 2024